MUSC Psychiatry Chair Update
February 2016

Thomas W. Uhde, MD
Department of Psychiatry and
Behavioral Sciences & Institute of Psychiatry
I am extremely pleased to announce an important leadership appointment in the Department. Effective immediately, Dr. Jeffrey Cluver will take on the role of Deputy Chair for the Department of Psychiatry & Behavioral Sciences. This is a strategic addition to our administrative leadership structure that is in alignment with the reorganization that is taking place across the university and medical center.

In this position Dr. Cluver will serve as an extension of the Chair and have the authority to make autonomous decisions at the Department level. While he will have the authority to oversee all aspects of the Department, Dr. Cluver’s primary responsibility will be the clinical operations of the department. He will also continue to lead the education and training programs in his role as Vice Chair for Education & Training. Dr. Cluver will continue to be the Associate Medical Director for the Mental Health Service Line and Director of the Psychiatry Hospitalists Division.

Over the years, Dr. Cluver has served in many different leadership roles in the Department and at the VA, and he has a proven track record of being an outstanding administrator and leader. I am confident that in this new role he will help to ensure the continued success of our Department as we navigate the reorganization of MUSC Health and our healthcare system.

Please join me in congratulating Dr. Cluver and welcoming him to this new and critically important leadership role in the Department.
Dr. Horner completed his A.B. at Harvard University, his Ph.D. in psychology at Emory University, and a postdoctoral fellowship in clinical neuropsychology at UCLA. He joined the MUSC faculty in 1994. He is currently Director of the Neuropsychology Clinic at the Ralph H. Johnson VA Medical Center, and Professor of Psychiatry and Behavioral Sciences at MUSC.

His clinical interests broadly include the assessment of cognition, psychopathology, and personality in individuals with neurological and psychiatric conditions. In addition to providing evaluations through the Neuropsychology Clinic, he is Clinical Co-Director of the VA Memory Disorders Clinic, and sees patients in the TBI Clinic. He supervises psychology interns in all of these settings, and is Director of Evaluation for the Charleston Consortium Clinical Psychology Internship Program (MUSC and Ralph H. Johnson VA Medical Center). He has been teaching first-year medical students since some time near the end of the last century.

Dr. Horner’s main research interests concern validity in clinical neuropsychological assessment, including the use of performance validity indices to detect inadequate effort on clinical examination. He is also interested in the characteristics of individuals who provide noncredible clinical data, and in the development of techniques to decrease the occurrence of inadequate effort on clinical examination. In addition, he has published in the areas of traumatic brain injury, PTSD, and substance use disorders. Dr. Horner has recently been funded (as Principal Investigator or Co-Investigator) by the National Academy of Neuropsychology, the Department of Veterans Affairs, and the National Institute of Mental Health.

Dr. Horner has been happily married for 24 years, and has two wonderful children, Logan (15) and Liana (12). Outside of work, he enjoys photography, very strong coffee, and music – especially rock, reggae, classical, baroque, opera, blues, world, and some other stuff that isn’t easily classified. He also enjoys writing overblown, narcissistic-sounding profiles of himself for Department publications.
Baron Short completed his B.S. in Biology from the University of South Carolina Honors College in 1996 and his M.D. from the Medical University of South Carolina in 2001. In 2006, he finished his dual residency in Internal Medicine and Psychiatry at MUSC and joined the faculty as an Assistant Professor with dual appointments in the Department of Psychiatry and Behavioral Sciences and the Department of Medicine. He completed a Masters of Science in Clinical Research in 2009. Currently, he is an Associate Professor in the Brain Stimulation Laboratory Division in the Department of Psychiatry and Behavioral Sciences. He serves as the Medical Director for the Brain Stimulation Service and as an Informatics Medical Director for MUSC.

Dr. Short employs a variety of brain stimulation technologies for neuropsychiatric disorders, such as treatment resistant depression, schizophrenia, and OCD. He directs the Brain Stimulation Service, wherein patients are seen in consultation to determine if they may be eligible for brain stimulation treatments such as electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), or deep brain stimulation (DBS). The original clinic is located at the Institute of Psychiatry. A second TMS clinic in Mt. Pleasant was established in 2014, and he is actively expanding activities at both sites. Dr. Short’s research has primarily involved brain stimulation technologies. He was the PI for studying TMS for fibromyalgia, and is a coinvestigator in several ECT, TMS, and TCDCS trials as a member of the Brain Stimulation Lab.

He lives in Charleston, SC with his wife and 2 daughters. He enjoys metatheoretical philosophy, coaching soccer, the outdoors, and barbecuing.
Dr. Howard C. Becker is a Professor in the Addiction Sciences Division in the Department of Psychiatry and Behavioral Sciences, and he holds a dual appointment as Professor in the Department of Neuroscience at the Medical University of South Carolina (MUSC). He also holds the position of Research Career Scientist at the RHJ Department of Veterans Affairs Medical Center that is affiliated with MUSC. Dr. Becker received his B.S. in Biology at the State University of New York at Buffalo and his M.S. and Ph.D. in Psychobiology at Rutgers University. After postdoctoral training in alcohol/addiction psychiatry research, he joined the faculty at MUSC in 1985.

Dr. Becker is the Director of the Charleston Alcohol Research Center (ARC), orchestrating all administrative, research, and educational outreach activities in connection with this NIH/NIAAA-supported national research center of excellence. The Charleston ARC embraces a multidisciplinary and translational-oriented research program with a general focus on treatment and treatment implications for alcohol use disorders. Dr. Becker recently led the effort to successfully secure funding for an additional 5-year renewal period (2016-2020) for the Charleston ARC. He also serves as the Scientific Director of the national multi-site NIAAA-supported Integrative Neuroscience Initiative on Alcoholism (INIAstress) Consortium, which includes multidisciplinary approaches in studying the complex relationship between stress and alcohol use/misuse.

Dr. Becker is an established investigator in the alcohol and addiction neuroscience field. He has over 30 years of experience in addressing clinically relevant questions regarding alcohol addiction and mechanisms of alcohol actions in the brain. The overall focus of his research program is elucidating biological underpinnings and environmental factors that govern sensitivity to alcohol, as well as adaptive changes resulting from chronic alcohol exposure that play a role in driving/promoting excessive alcohol drinking and enhanced relapse vulnerability. His research program utilizes behavioral, neurochemical, and molecular biology approaches in studying brain mechanisms that facilitate transition to uncontrolled drinking, with the goal of identifying and evaluating new therapeutic targets and strategies for treating problem drinking and alcoholism. Dr. Becker’s research program has been continually supported by multiple concurrent grants from the NIH and VA Medical Research for over 30 years. He is widely recognized as a leader in the alcohol research field, as evidenced by his published research accomplishments, editorial and grant reviewing service, and being frequently invited to present his research findings at numerous national and international scientific conferences.

Dr. Becker is actively engaged in educational and training programs, having mentored numerous graduate and postdoctoral students in alcohol research. He provides mentorship and guidance for several junior faculty (both basic researchers and clinical investigators) in supporting their career development in the alcohol research field.
Cynthia Cupit Swenson, a clinical research Psychologist, is Professor of Psychiatry and Behavioral Sciences in the Department of Psychiatry and Behavioral Sciences. She completed her doctoral studies in clinical psychology at Florida State University. Her internship and post-doctoral fellowship in child and pediatric psychology were also completed at MUSC. During her post-doctoral fellowship, she became interested in clinical work and research on child abuse and neglect due to her work at Dee Norton Lowcountry Children’s Center and the National Crime Victim’s Center. She joined Family Services Research Center to work with Dr. Scott Henggeler on development of a Multisystemic Therapy-based treatment model for families experiencing physical abuse and/or neglect of a child. While pursuing funding to conduct the research on this child maltreatment model, Dr. Swenson directed a community violence prevention project called Neighborhood Solutions in the Union Heights neighborhood of North Charleston.

Child Abuse and Neglect Treatment Model
Through a 5-year NIMH grant, Dr. Swenson conducted a randomized trial to evaluate the effectiveness of Multisystemic Therapy for Child Abuse and Neglect (MST-CAN). The success for families shown in the randomized trial led to dissemination of the MST-CAN model in 2 sites in Switzerland, 3 sites in the Netherlands, 5 sites in England, and 8 sites in New York City covering all boroughs. As the MST-CAN research was completed, the state of Connecticut asked Drs. Swenson, Henggeler, and Cindy Schaeffer to specialize the MST-CAN model for families experiencing physical abuse and/or neglect plus parental substance abuse. The model that came out of this work is called MST-Building Stronger Families (MST-BSF). A quazi-experimental study funded by the Annie E. Casey Foundation and Connecticut Department of Children and Families (DCF) showed greater effectiveness for MST-BSF in reducing reabuse and out-of-home placement of children than comprehensive community services. These results led to NIDA funding for a 5-year randomized trial that is in its final year. The need was so great and research so sparse for families with this co-occurring problem, that the state of Connecticut spread the model to 6 sites. The success of MST-BSF led the state of Connecticut to ask Drs. Swenson and Schaeffer to further develop this model to extend to families experiencing abuse and neglect plus intimate partner violence. They have just completed development of this model called MST for Intimate Partner Violence (MST-IPV) with support of the Annie E. Casey Foundation and DCF.

The Neighborhood Project and Beyond
The Neighborhood Solutions Project resulted in an 85% reduction in calls for police service, reductions in substance abuse, violence, and school expulsion among youth involved. Neighborhood Solutions is described in a book written by MUSC and neighborhood residents. Importantly, the prosocial activities designed by the community and MUSC Project staff that highlighted an African cultural heritage led the neighborhood collaborators to Ghana, West Africa in 2006. In 2007 Drs. Swenson and Samuel Nkrumah Yeboah founded Project OKURASE, an NGO in a rural village in the eastern region. In conjunction with the Chief, Elders, village residents and others from Charleston, five objectives were developed for a sustainable teaching village to address life threatening problems that are common in rural African villages. These objectives focus primarily on women and orphans and vulnerable children and from a grassroots level address: 1) water and sanitation; 2) health and nutrition; 3) economic sustainability; 4) education and technology; and, 5) buildings and energy sources. Significant gains have been made toward each of these objectives. The village plans to open a vocational school and medical center being completed from all local labor soon. High school students and university interns from all over the world have come to Okurase to participate in service learning. Project Video: https://www.youtube.com/watch?v=l4vHdG70OvE
MEET LAURA SEEBACK

We are excited to welcome Laura Seeback, in her role as the Continuing Education Coordinator for the Department of Psychiatry and Behavioral Sciences. She is very enthusiastic about the opportunity to join the team of Dr. Milanak, Dr. Cluver and Melissa Jacob as they continue to expand our Continuing Education program.

Laura graduated summa cum laude from the University of North Florida with a Bachelor of Fine Arts degree in Painting and Drawing. She has spent the past five years with Colliers International Northeast Florida, a commercial real estate firm in Jacksonville, Florida, providing marketing, research and real estate representation for many national retailers. She is eager to use her talents and skills to contribute to the successful and fast-growing continuing education program, and looks forward to meeting all of the members of our large department.

USNWR RANKINGS

Dear Faculty,

I am writing to encourage your support in helping MUSC’s Department of Psychiatry & Behavioral Sciences be recognized and ranked as one of the top departments in the country. U.S. News & World Report has partnered with Doximity, a web-based physician network, to survey physicians as a component of their data gathering for the annual Best Hospital rankings. Online votes from Doximity members, along with paper surveys mailed to a sample of non-Doximity members, will help determine the reputation portion of the scores. As this is also the group that now ranks residency programs, there is some added incentive to belong and participate overtime, particularly for alumni.

If you have not already created your free physician profile in Doximity, please take a moment to register and complete your profile now so that you will have an opportunity to vote in this year’s survey (www.doximity.com).

Please complete your registration by February 26, 2016 so that you can participate this year.
The Charleston Consortium Internship is very pleased to present the 2016-17 internship class. The 19 interns represented here represent 16 different graduate programs from across the country, ranging from the North (Central Michigan University) to the South (Florida International University), and from the East (Virginia Commonwealth University) to the West (University of Oregon), along with a very healthy dose of the Midwest (Memphis, Kansas, Kent State, Purdue, Ohio University, etc.).

As in previous years, this class of interns is remarkably accomplished with respect to their academic achievements. The average number of peer-reviewed journal articles among this class is 8.3 (range 4-17, median 7). The average number of first-authored publications is 4 (range 2-10). This class includes two Spanish speakers, one German speaker, and one speaker of both Twi and Krobo (look them up!). Members of this class have also had their research funded by NIDA, the American Psychological Foundation, the American Psychological Association, and the Ford Foundation, and two members serve on journal editorial boards.

We look forward to welcoming this class in August, and we hope you will join us in celebrating their arrival.
The Chairman of the Department of Psychiatry and Behavioral Sciences is pleased to announce a new submission cycle for the Chair’s Research Development Fund (CRDF). Applications will be accepted until midnight, May 1st. The CRDF supports several goals related to maintaining high quality research training programs. The primary goals are to increase the number of extramurally-funded junior investigators, encourage integration of trainees into research projects, enhance mentor-mentee collaborations within and across department divisions, and increase minority representation among funded junior investigators.

For more information, please contact Vickey Cornelison-Grant at cornelv@musc.edu, or call her at 792-5879.

For anyone who is requesting promotion or tenure effective January 1, 2017, all promotion and tenure requests must be received in the Chairman’s office no later than February 9, 2016, in the form of complete packets accompanied by a letter of recommendation from your Division Director. Packets with checklists, requests for materials, and forms specific for regular and modified faculty have been developed to make the submission process more straightforward. Packets are available on the College of Medicine’s website. Follow this link: http://academicdepartments.musc.edu/com/faculty/apt/musc/index.html. The letter of recommendation from your Division Director must follow appendix 2 in the COM APT guidelines. Division Director letters should include the following paragraphs: introductory, education, research if applicable, scholarly publications, clinical practice if applicable, administration, and other activities and accomplishments. If you have any questions, please contact Kristen Mulholland mulhollk@musc.edu.
BREAKFAST WITH THE CHAIR

I have implemented monthly breakfast meetings. These meetings are intended to have an open-ended discussion with the Chair regarding education/training, clinical service, and/or research opportunities and future strategic plans. Available dates in 2016 include: March 15, April 12, May 24, June 21, July 19, September 13, October 11, and November 15. Breakfast meetings will be held from 8:30am-9:30am in the Chairman’s conference room and are open to a maximum of 12 faculty members. Interested faculty members should contact Kristen Mulholland (mulhollk@musc.edu) to sign up for a breakfast meeting.

YOU’RE INVITED

You are cordially invited to the Department of Psychiatry & Behavioral Sciences

Faculty Reception
March 1, 2016

Wickliffe House
5pm-7pm

Please RSVP to Kristen Mulholland (mulhollk@musc.edu) by February 22, 2016.
GRAND ROUNDS
HIV and Mental Illness: A Case for Integrated Care
Presented by: Daena L. Petersen, MD, MPH, MA
MUSC Psychiatry Resident, PGY4
APA Public Psychiatry Fellow and Chairperson

FEBRUARY 26 GRAND ROUNDS
Title: Impulsivity and Mental Health

Speaker:
Zachary W. Adams, PhD
Assistant Professor
National Crime Victims Research & Treatment Center
Department of Psychiatry and Behavioral Sciences
Medical University of South Carolina

GRANT AWARD ACTIVITY
1.1.16-1.31.16

<table>
<thead>
<tr>
<th>PI Name</th>
<th>Title</th>
<th>Type of Application</th>
</tr>
</thead>
<tbody>
<tr>
<td>Howard Becker</td>
<td>IPA Laura Ralston - Role of BDNF in Stress Effected on Ethanol Dependence-Induced Escalated Drinking</td>
<td>New</td>
</tr>
<tr>
<td>Howard Becker</td>
<td>Role of BDF in Ethanol Dependence and Escalation of Drinking</td>
<td>Competing Continuation</td>
</tr>
<tr>
<td>Jeffrey Borckardt</td>
<td>Interprofessional Prevention Education Institute Evaluation Subgrant</td>
<td>New</td>
</tr>
<tr>
<td>Kathleen Brady</td>
<td>Clinical Scientists Training in Addictions at MUSC</td>
<td>Non-Competing Continuation</td>
</tr>
<tr>
<td>Kathleen Brady</td>
<td>The Doris Duke Charitable Foundation Fund: Fund to Retain Clinical Scientists</td>
<td>New</td>
</tr>
<tr>
<td>K. Michael Cummings</td>
<td>A Community Trial to Speed Diffusion of Smoke Free Multiunit Housing Policies</td>
<td>Non-Competing Continuation</td>
</tr>
<tr>
<td>Daniel Gros</td>
<td>Transdiagnostic Psychotherapy for Veterans with Mood and Anxiety Disorders</td>
<td>New</td>
</tr>
<tr>
<td>Connie Guille</td>
<td>Establishing a Regional Telemedicine Program to Reduce Prescription Opioid Use During Pregnancy</td>
<td>New</td>
</tr>
<tr>
<td>Robert Malcolm</td>
<td>An Open-label, Long-term, Safety and Efficacy Study of Intrasanal Esketamine in Treatment-resistant Depression</td>
<td>New</td>
</tr>
<tr>
<td>James Prisciandaro</td>
<td>A Neuroimaging Investigation of Recovery from Substance Dependence in Individuals with Bipolar Disorder</td>
<td>New</td>
</tr>
<tr>
<td>Alyssa Rheingold</td>
<td>Comprehensive Mental Health Care for Adult Victims of Crime 2015</td>
<td>New</td>
</tr>
<tr>
<td>Cynthia Swenson</td>
<td>MST Model with a Child Maltreatment</td>
<td>Non-Competing Continuation</td>
</tr>
</tbody>
</table>
The Adult General Psychiatry Clinic in the Community and Public Safety Psychiatry Division of the Department of Psychiatry and Behavioral Sciences began a Psychopharmacology Clinic on January 5, 2016. This clinic provides medication management appointments and has a mission to integrate advanced psychopharmacology into outpatient practice.

The Adult General Psychiatry Clinic is piloting this Inter-professional Psychopharmacology clinic to include a training opportunity for residents. This clinic occurs weekly on Tuesday afternoons under the supervision of Frampton Gwynette, M.D., the attending physician and Clinic Director. A Pharm D Attending is also available on site during the hours of clinic operation. The Pharm D staffing is coordinated by Amy VandenBerg, Pharm D, the Psychiatry Pharmacy Residency Program Director and Institute of Psychiatry Pharmacy Coordinator.

Patient appointments for medication management can be scheduled by contacting the Outpatient Psychiatry Scheduling staff at 792-9162.

**KUDOS/WINS**

- Dr. Cynthia Swenson and Health Outreach lead massage therapist in Ghana wrote up a case study regarding women suffering from neck and back pains from headpanning. Their case study received the Gold Prize from the Practitioner Case Report Contest.

- Drs. Pat O’Neil and Josh Brown will represent MUSC in the South Carolina Obesity Initiative established through Health Sciences South Carolina.

- Dr. Gregg Dwyer was featured on the front page of the Post and Courier discussing research within the Community and Public Safety Psychiatry Division. [http://www.postandcourier.com/article/20160111/PC16/160119279](http://www.postandcourier.com/article/20160111/PC16/160119279)

- The Charleston Alcohol Research Center is currently highlighted on the MUSC PR site. [musc.edu/pr/newscenter/2016/MUSC-alcohol-research-center.html](http://musc.edu/pr/newscenter/2016/MUSC-alcohol-research-center.html)

- Dr. Kathleen Brady was named Vice President for Research

- The Community and Public Safety Psychiatry Division (CPSPD) has filled their postdoctoral fellowship position. Dr. Kathryn Jameson, from Xavier University, will be joining CPSPD in the fall.
ATTENTION CLINICIANS

Appointment to the Medical Staff at MUSC is a privilege. It is your responsibility to read and understand the MUSC Medical Center Medical Staff Bylaws. The Medical Staff Bylaws can be found online [http://mcintranet.musc.edu/quality/departments/medicalstaffoffice/CAP/](http://mcintranet.musc.edu/quality/departments/medicalstaffoffice/CAP/).

Also, please pay close attention to the Statements/Attestation section when you apply for appointment or credentialing. When a practitioner applies for appointment or reappointment, he/she responds to these queries:

**Voluntary/Involuntary Actions**

*Have you voluntarily or involuntarily limited, reduced, not renewed or terminated any of the following:
- License(s) - DEA or DHEC License(s) - Clinical privilege/Protocol at any hospital – Staff membership on any hospital staff, HMO/PPO or managed care entity

*Have you voluntarily or involuntarily had any of the following limited, suspended, reduced, revoked or terminated? - License(s) - DEA or DHEC license(s) - Clinical privilege/Protocol at any hospital – Staff membership on any hospital staff, HMO/PPO or managed care entity

*Are you aware of any previously successful or currently pending challenges (including, and not limited to any reprimand) to any of the following: - License(s) - DEA or DHEC license(s) - Clinical privilege/Protocol at any hospital – Staff membership on any hospital staff, HMO/PPO or managed care entity

Additionally, he/she attests as follows (Attestation):

*I acknowledge that any significant misstatements in, or omissions from the application or supporting information, may constitute cause for denial of reappointment or cause for summary dismissal;

*I acknowledge that I have received and read, or been given access to, any manuals or policies relevant to the application process and generally to clinical practice at the Medical Center, and agree to be bound to the terms thereof in all matters relating to Medical Staff membership and clinical privileges;

*I pledge to maintain an ethical practice, to provide for continuous care for my patients, and to refrain from delegating the responsibility of care for my patients to any practitioner not qualified to undertake that responsibility;

*I agree to notify the Medical Center within five (5) working days if I should become subject to any disciplinary action, or if I voluntarily relinquish any licensure, certification, membership or privileges at any other medical facility or organization, or if I voluntarily relinquish my ability to participate in the Medicare or Medicaid programs, or if any challenges to the above are submitted; and

*I certify that all information submitted by me in support of this application is true to the best of my knowledge and belief.
SELECTED PUBLICATIONS


CONGRATULATIONS!

2016 SCPA Meeting Poster Competition
Zac Zuschlag, DO

3rd Place

2016 SCPA Meeting Poster Competition
Daena Petersen, MD., MPH

2nd Place
PRESENTATIONS

Thomas Lewis, MD
Presented
LGBT Patients: Legal and Ethical Considerations.
at the
2016 SCPA ANNUAL MEETING

Edward M. Kantor, MD
and
David R. Beckert, MD
Presented
Disaster Psychiatry: Thoughtful Integration Into The Response
at the
2016 SCPA ANNUAL MEETING
STUDENTS, RESIDENTS, & FACULTY

The Student Psychiatry Interest Group (SPIG) invites you to join us for an evening of delicious food and engaging conversation with others interested in Psychiatry at this year’s…

ANNUAL SPIG SOIREE

FEBRUARY 17, 2016
4:30 p.m. – 6:30 p.m.
Drug Discovery Building Lobby

The American Psychiatric Association Certificate of Recognition to Medical University of South Carolina for achieving APA 100% Club Gold Level 2015-2016

Rahn K. Bailey, MD, DFAPA
Chairperson, APA Membership Committee
American Psychiatric Association

Saul Levin, M.D., M.P.A
CEO & Medical Director
American Psychiatric Association
Use and Interpretation of New Lab Tests (Biomarker) for Assessing Drinking and Relapse in Psychiatric, Medical, and Addiction Patients

How Can They Assist Diagnosis and Treatment?

Featuring
Raymond F. Anton, MD
Director, Clinical Neurobiology Laboratory
Medical University of South Carolina

Friday, March 4, 2016
Medical University of South Carolina, Charleston, SC
Bioengineering Building, Room 110
8:00 a.m. - 12:00 p.m.

Alcohol consumption levels vary widely, but high consumption can lead to various health consequences, including high blood pressure and GI symptoms, as well as various psychiatric symptoms including anxiety, depression, insomnia, impulsivity, and family/work disruption.

There are now at least 3 laboratory-based tests (biomarkers) of alcohol consumption that detect amounts as low as one or two drinks (Urinary Ethylglucuronide and Blood Phosphatidyl Ethanol) and/or indicate only when heavy drinking is present (Carbohydrate Deficient Transferrin). These markers can be used to assist identification and diagnosis of Alcohol Use Disorder, or in monitoring alcohol consumption over time.

Dr. Anton, an international expert in the development and use of these biomarkers, will present an overview of these tests, how they are measured, and data supporting their use. Dr. Sarah Book (Medical Director of the Center for Drug and Alcohol Programs) supervises the use of these tests in the clinic and instructs residents and medical students in their use and interpretation. She will present case histories and discuss clinical profiles and uses of these tests.

<table>
<thead>
<tr>
<th>Registration Type</th>
<th>General Registration (1/5/16 - 2/12/16)</th>
<th>Late Registration (On or After 2/13/16)</th>
</tr>
</thead>
<tbody>
<tr>
<td>MD’s, DO’s, PharmD’s</td>
<td>$125.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>All Other Providers</td>
<td>$105.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Students/Trainees</td>
<td>$60.00</td>
<td>$85.00</td>
</tr>
</tbody>
</table>

Please Note: Registration and payment must be received within the registration deadlines to be eligible for that rate.

CME/CEU’s Available to Attendees - See Website for More Information

To register online for this training and view our upcoming calendar of events, visit us at:
www.musc.edu/psychevents

Questions? Contact us at: psych-events@musc.edu or (843) 792-0175
To Institute of Psychiatry Health Care Providers:

This year, the Institute of Psychiatry Patient Family Advisory Council will celebrate 5 years of supporting the patients and families we serve by strengthening partnerships among patients, families, health care providers and our community. Over these years, the council has experienced some natural attrition and needs to recruit additional council members to boost its membership. Therefore, the council is requesting your assistance with a council member recruitment campaign (recruitment flyer for distributing / displaying attached).

We are asking our Institute of Psychiatry health care providers to consider and identify patients or family members who would make a meaningful contribution to this council. The candidates must:

- have a patient or family member experience through inpatient and/or outpatient services of the Institute of Psychiatry.
- be able to participate in MUSC Volunteer Services screenings and orientation activities.
- be able to attend monthly meetings, share input and participate in council projects.
- be positive and supportive of the MUSC’s mission and standards of professional behavior.
- be able to see beyond their own personal experiences.
- listen well and respect the perspectives of others.
- be able to speak comfortably in a group with candor and work in partnership with others.

Patients and family members can bring valuable perspectives about their treatment experiences at the Institute of Psychiatry and provide unique insights into the strengths and challenges of the mental health care system. The IOP Patient Family Advisory Council has been an active and productive team of volunteers. Council members have shared their recovery stories as part of IOP department orientation, participated on committees and process improvement teams, facilitated programs that promote mental illness education and awareness and utilized grants to fund projects that support recovery.

Please send the names of patients and/or family members and contact information to: Bryan Counts, IOP Patient Safety & Service Coordinator: countsbc@musc.edu / 792-6259.
Cutting Edge: What’s New In Sex Offender Treatment and Assessment

Come join us for a day long training and conference to discover what’s new and current in the field of Sex Offender Treatment.

**Friday, February 5, 2016**
Medical University of South Carolina
Bioengineering Building, Room 110
9 a.m. - 4:30 p.m.

This training offers presentations by local experts in the areas of assessment and treatment of adults, juveniles, and female sex offenders. The day will conclude with an open panel discussion with the board members of our state chapter of ATSA. So bring your questions and receive some expert advice.

This is a great opportunity to network with other individuals who work in the field and to establish relationships to assist in becoming a member of the national organization.

We look forward to seeing you all at this event.

### Registration Fees:

<table>
<thead>
<tr>
<th>Category</th>
<th>Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>MD’s, DO’s, PharmD’s</td>
<td>$200.00</td>
</tr>
<tr>
<td>Other Providers</td>
<td>$150.00</td>
</tr>
<tr>
<td>Students/Trainees</td>
<td>$100.00</td>
</tr>
</tbody>
</table>

CEU’s are available to attendees

To register online for this training and view all our upcoming events, visit us at:

[www.musc.edu/psychevents](http://www.musc.edu/psychevents)

Questions? Contact us at: psych-events@musc.edu or (843) 792-0175
Sleep & Anxiety Treatment & Research Program (SATRP)

The Sleep & Anxiety Treatment & Research Program (SATRP) provides assessment, therapy, and medication management for individuals seeking treatment for anxiety disorders (e.g., Panic Disorder, Generalized Anxiety Disorder, Obsessive-Compulsive Disorder, Social Anxiety Disorder, Post-traumatic Stress Disorder, Specific Phobias) and/or sleep disorders (e.g., Insomnia, Recurrent Sleep Paralysis, Sleep Panic, Nightmares, Narcolepsy, REM Behavioral sleep disorders).

Patients complete a thorough initial intake assessment and receive a personalized treatment plan, which may include individual and/or group therapy and/or medication management.

Services:
- Individual Therapy
- Group Therapy (Anxiety Group and Insomnia Group – Friday Afternoons – Rolling Admissions)
- Medication Management

Clinic Directors:
- Thomas W. Uhde, M.D.
- Alyssa Rheingold, Ph.D.

Clinic Coordinator:
- Melissa E. Milanak, Ph.D.
- Email: Milanak@musc.edu
- Phone: (843) 792-0042

Providers:
- 1 Licensed Clinical Psychologist
- 1 Clinical Psychology Post-doctoral Fellow
- 2 Clinical Psychology Pre-doctoral Interns
- 1 Psychiatry Resident

Referrals:
- Providers can directly send MRN via email to Dr. Milanak (Milanak@musc.edu)
- Providers can send Dr. Milanak an EPIC in-basket message
- Providers can refer via EPIC by CC’ing Dr. Milanak on the chart
- Patients can call Psychiatry Scheduling (843-792-9162) to request an appointment with SATRP*
  *Please do not give patients Dr. Milanak’s direct phone number or email address.

Questions & Additional Information:
- Contact Dr. Milanak via email (Milanak@musc.edu) or phone (843-792-0042)

Note: Patients seeking diagnostic sleep studies for Obstructive Sleep Apnea (OSA) should contact MUSC’s Sleep Center.
Psychiatry Continuing Education
2016 Events Calendar

February 2016
5th - Cutting Edge: What’s New In Sex Offender Treatment and Assessment
26th - TTS - Cognitive Processing Therapy (CPT)

March 2016
4th - TTS - Use and Interpretation of New Lab Tests (biomarkers) For Assessing Drinking and Relapse In Psychiatric, Medical, and Addiction Patients. How can they assist diagnosis and treatment? (1/2 day)

April 2016
22nd - 2nd Annual Spring Social Work Conference
28th - TTS - Grief & Bereavement Techniques*
29th - TTS - Depression & Suicidal Ideation*

May 2016
20th - TTS - Management of Peri-Partum Depression (1/2 Day)

June 2016
2nd & 3rd - 29th Annual Update in Psychiatry
Trending Topics in Substance Abuse

*Register for both conferences and receive a special two-day rate.

Contact us: psych-events@musc.edu or (843)792-0175
Visit our website for information and registration for all our Continuing Education Events:
www.musc.edu/psychevents
ADDICTION RESEARCH SEMINAR

“Reproductive regulation of affective state: context and complexity”

DAVID RUBINOW, MD

Assad Meymandi Distinguished Professor and Chair of Psychiatry
Professor of Medicine
Director, UNC Innovation and Health Care System Transformation
Director, UNC Center for Women’s Mood Disorders
UNC, Chapel Hill

Thursday, February 4, 2016
12:00 PM

Bioengineering Building Auditorium, 110

*CE credits available

Sponsored by the Women’s Research Center, the Charleston Alcohol Research Center, and the Neurobiology of Addictions Research Center.
The Fourth Annual

Women’s Health Research Day
Sponsored by MUSC’s Women’s Health Research Center & SCTR Institute

Thursday, February 4, 2016
9:00AM - 2:00PM (Registration at 8:30am)
MUSC Bioengineering Building Auditorium (Room 110)

Keynote Speakers

David Rubinow, MD
Assad Meymandi Distinguished Professor and Chair of Psychiatry; Professor of Medicine; Director, UNC Innovation and Health Care System Transformation; and Director, UNC Center for Women’s Mood Disorders, UNC, Chapel Hill

Keynote:
Hormone-Sensitive Regulation of Affect in Women

Carol Wagner, MD, FAAP
Professor of Pediatrics, Neonatology; Associate Director, Neonatal-Perinatal Fellowship Program; Associate Director, Clinical and Translational Research Center, MUSC

Keynote:
Health Effects of Vitamin D Deficiency vs. Sufficiency in Pregnant and Lactating Women

Online Registration is FREE BUT REQUIRED

To attend Women’s Health Research Day, please register by noon on Monday, February 1, 2016

Breakfast and Lunch provided to attendees

Visit musc.edu/wrc for more information!
Contact Ford Simmons at simmonw@musc.edu or 843-792-2994
Cognitive Processing Therapy (CPT)
Friday, February 26, 2016
Medical University of South Carolina
Gazes Auditorium, Strom Thurmond Bldg., Room 125
8:30 a.m. - 4:30 p.m.

Many trauma survivors may find that they get “stuck” in their thoughts about the trauma and how it negatively impacts their life, which can inhibit a survivor’s ability to heal from the event. Cognitive Processing Therapy is a 12 session empirically supported treatment aimed at helping survivors process the trauma and challenge “stuck points” that negatively impact how survivors see themselves, others, and the world. By learning more adaptive appraisals, survivors can effectively begin to heal from their experiences.

In this one-day workshop, which is part of our new Therapeutic Techniques & Special Populations Series, clinicians will be provided with an informational overview of Cognitive Processing Therapy.

Details of how to receive formal training in Cognitive Processing Therapy to be considered a certified “CPT Provider” will be provided.

Presented by:
Rachel E. LeVine, Ph.D.
PCMHI/CBT Team; MST Service Provider
Ralph H. Johnson VAMC
Assistant Professor of Psychiatry and Behavioral Sciences

Registration Fees:

<table>
<thead>
<tr>
<th></th>
<th>Early Registration (before 01/09/16)</th>
<th>General Registration (1/10/16 - 2/14/16)</th>
<th>Late Registration (on or after 2/15/16)</th>
</tr>
</thead>
<tbody>
<tr>
<td>MDs *</td>
<td>$185</td>
<td>$210</td>
<td>$235</td>
</tr>
<tr>
<td>All Other Providers</td>
<td>$150</td>
<td>$175</td>
<td>$200</td>
</tr>
<tr>
<td>Students &amp; Trainees</td>
<td>$50</td>
<td>$75</td>
<td>$100</td>
</tr>
</tbody>
</table>

Online registration: www.musc.edu/psychevents

CME/CE credits available

Contact us: psych-events@musc.edu or (843)792-0175
Visit our website for information on all our Continuing Education Events:
www.musc.edu/psychevents
Title: rTMS for Adolescent Depression -- upcoming in the next couple weeks  
Contact: Annabel Franz, franza@musc.edu, 843-876-5141  
Description: We are investigating the safety and efficacy of repetitive TMS as a treatment for adolescent depression for those aged 12-21 years old. We are seeking adolescents of this age range who have not received sufficient benefit from at least one antidepressant medication trial. TMS is currently FDA approved for treating adult depression.

Title: rTMS for Bipolar Depression - current  
Contact: Annabel Franz, franza@musc.edu, 843-876-5141  
Description: We are investigating repetitive TMS as a treatment for bipolar depression in conjunction with mood stabilizers in adults aged 22-68 years old. We are seeking treatment refractory patients with bipolar disorder. TMS is currently FDA approved for treating adult depression.

Title: rTMS for Reducing Marijuana Craving and Risky Behaviors in Non-Treatment Seeking Heavy Marijuana Smokers - current  
Contact: Annabel Franz, franza@musc.edu, 843-876-5141  
Description: A pilot trial investigating how TMS to the left dorso-lateral pre-frontal cortex can reduce marijuana craving and impulsive decisions in adults 18-60.

Title: Enhancing Disrupted Reconsolidation: Impact on Cocaine Craving, Reactivity & Use  
Contact: Amanda Smith, smitham@musc.edu, 792-6984  
Description: The purpose of this double-blind, placebo-controlled study is to examine whether beta-adrenergic antagonist propranolol can attenuate cocaine-associated memories and thereby reduce cocaine craving, cue reactivity, and use in cocaine dependent participants. Participants will receive either placebo, 40mg, or 80mg of propranolol after each of two laboratory sessions of cocaine cue exposure. Participants will be evaluated on cocaine craving, physiological reactivity to cocaine cues, and cocaine use in follow-up sessions for 6 weeks.

Title: Traumatic Exposure and Competency to Stand Trial: Describing Juvenile Offender Characteristics.  
Contact: Sheresha Christopher, chrishe@musc.edu, 792-1461  
Description: Exposure to traumatic events is associated with trauma sequelae which has been studied and observed in samples of justice-involved youth. Within this population, a small subset of youth is referred for evaluation of their competency to stand trial due to concerns they may be lacking a factual and rational understanding of the proceedings against them and the ability to assist their attorney in their defense. Despite the high prevalence of trauma exposure and the similarity of deficits observed, little is known about trauma exposure in youth thought to exhibit deficits in those abilities typically associated with competency to stand trial. The current study aims to describe the differences in characteristics between juveniles who are opined competent to stand trial and those who are not. A particular emphasis is placed on the presence and type of past trauma exposure in relation to the nature of the criminal offenses given the high prevalence of trauma in this population.
**Title:** Comparison of Pre-Trial Competency to Stand Trial Defendants’ Characteristics on Outcome of Feigning Measures: A Preliminary Study of Local Norms  
**Contact:** Jennifer Steadham, steadhaj@musc.edu, 876-2140  
**Description:** Deliberate attempts to falsify, fabricate, or grossly exaggerate some aspect of functioning is known as feigning. When feigning is motivated by possibility of external gains (e.g., avoidance of prosecution or lesser punishment), it is known as malingering (Rogers & Shuman, 2005). Malingering has obvious relevance in forensic mental health evaluations, as pre-trial criminal defendants have clear motivations to feign impairment. Feigning strategies can be subdivided into two varieties in criminal forensic contexts: cognitive (i.e., memory or thinking processes) and psychiatric (i.e., symptoms of major mental disorders) impairment. Categorical classifications can be made on the basis of a defendant’s performance on feigning assessment measures, into groups thought to be exaggerating or fabricating impairment (“probable malingerers”) or those thought to be responding honestly (“non-malingerers”). In the last decade, direct examinations comparing the characteristics of competency defendants suspected of malingering versus non-malingerers, as classified by feigning measures, have been sparse and most often included as an incidental question in a larger study. For the current study, a sample of competence to stand trial evaluations conducted by MUSC’s Forensic Psychiatry Program will be reviewed. Competency to stand trial reports dated 2011 through August 2015 will be included for review. Evaluation reports will be coded for examinee (e.g., demographic, psychiatric diagnoses, and mental status descriptions) and evaluator characteristics (i.e., specialty field).

**Title:** CSP556 “rTMS for depressed veterans”  
**Contact:** Matt Schmidt, matthew.schmidt@va.gov, 843-577-5011 ext 5209  
**Description:** This is study for veterans only who have depression. The treatment given is Transcranial Magnetic stimulation. It is a double blind study with a sham (placebo) possibility. There is a screening phase of about 1 week, a treatment phase of 4-6 weeks, and a follow up phase where subjects come in once per month for 5 months. All procedures and assessments done at Ralph Johnson VA. Subject compensation is available up to $400.00.

**Title:** A Randomized Trial of E-cigarettes: Natural Uptake, Patterns and Impact of Use  
**Contact:** Caitlyn Hood, hooca@musc.edu, 843-876-2291  
**Description:** Electronic cigarettes (e-cigarettes) are the newest and perhaps the most popular non-cigarette products available to smokers. In this study, we will examine how the use of electronic cigarettes affects smoking behavior. Eligible participants will have a 2/3rds chance of receiving a sample of e-cigarettes. Participants must be current, daily cigarette smokers who are 18 years of age or older and interested in trying the e-cigarette.

**Title:** Oxytocin in Cocaine Dependence  
**Contact:** Lisa Nunn, jenkinli@musc.edu, 792-0476  
**Description:** This study explores the effect of oxytocin on stress response and brain reactivity in individuals with cocaine dependence. Participation consists of a screening visit, three outpatient study sessions, and two brief follow-up visits.
ONGOING STUDIES

Title: Effect of Pregnenolone on Cue-Reactivity in Marijuana-Dependent Individual.
Contact: Lisa Nunn, jenkinli@musc.edu, 792-0476
Description: This study explores the impact of an oral medication, pregnenolone, on drug craving following exposure to marijuana cues. Participation consists of a screening visit and one study session.

Title: Neural Substrates of Emotion: Impact of Cocaine Dependence
Contact: Lisa Nunn, jenkinli@musc.edu, 792-0476
Description: This study explores the effect of oxytocin on brain activity associated with stress in cocaine dependent individuals. Participation consists of a screening visit and one study session.

Title: A Randomized Controlled Trial of Varenicline for Adolescent Smoking Cessation (formal title protocol); Project Quit (nickname)
Contact: Referrals – Team Intake Coordinator; Study Management - Lori Ann Ueberroth, Study Coordinator
Contact email: Referrals – smokingstudy@musc.edu; Study Management – ueberro@musc.edu
Contact phone number: Referrals – 792-4097; Study Management – 792-8220
Description: This is a research study to determine if a medication (varenicline) helps young cigarette smokers quit. Smokers aged 14-21 who participate in the study receive medication or placebo and help with quitting during 12 weekly sessions. Smokers under 18 must have parental consent. There is no cost to participate and compensation is available to those that qualify.

Title: The gender-sex hormone interface with craving & stress-related changes in smoking (formal title protocol); SCOR 3 Nicotine (nickname)
Contact: Referrals – Team Intake Coordinator; Study Management - Lori Ann Ueberroth, Study Coordinator
Contact email: Referrals – smokingstudy@musc.edu; Study Management – ueberro@musc.edu
Contact phone number: Referrals – 792-4097; Study Management – 792-8220
Description: This is a non-treatment study for cigarette smokers ages 18-45, examining gender and reproductive hormone influences on smoking behavior. There is NO requirement that participants be interested in quitting smoking. The study involves 4 clinic visits and compensation is provided for those who qualify.

Title: Gabapentin for Relapse Prevention: Alcohol Withdrawal-Brain GABA/ Glutamate Effects
Contact: Konstantin Voronin, voronin@musc.edu, 792-4887
Description: This treatment study is an 16-weeks outpatient clinical trial where subjects will get medication, which might help them to reduce or stop their drinking, or a placebo. This study will recruit and randomize subjects who have expressed an interest in receiving treatment for alcohol dependence. Upon enrollment into this study there will be 11 outpatient visits. Each visit will last about 1-1.5 hours.
**Title:** Eagle Eye: Validation of computer-based saccade measures as a sensitive, reliable, and freely available biomarker for tracking subtle neurocognitive changes in Parkinson's disease.  
**Sponsor:** Michael J. Fox Foundation  
**Contact:** Jenna Renfroe, PhD.; renfroe@musc.edu ; 843-792-6096  
**Description:** This study aims to validate a computer-based task to enable clinicians and researchers to measure saccades without the cost and complexity of traditional eye-tracking equipment.

**Title:** Development and standardization of an iPhone-based application for quantitative measurement of the pupillary light reflex in healthy adults and patients with Parkinson’s disease. (iDilate)  
**Sponsor:** Chairs Departmental Research Foundation  
**Contact:** Jenna Renfroe, PhD; renfroe@musc.edu ; 843-792-6096  
**Description:** This aim of this project is to develop and standardize an application that would allow clinicians, researchers, and community-based safety personnel (e.g., police and EMS) to obtain quantitative measurements of the pupillary light reflex, a highly sensitive measure of neurological functioning.

**Title:** Atomoxetine Treatment for Cognitive Impairment in Parkinson’s Disease (ATM-Cog).  
**Sponsor:** Michael J. Fox Foundation  
**Contact:** Vanessa Hinson, MD, PhD.; hinsonvk@musc.edu ; 843-792-6096  
**Description:** This RCT assessing the safety and efficacy of ATM for cognitive impairment in Parkinson’s disease.

**Title:** Ranger Resilience and Improved Performance on phospholipid bound Omega-3’s (RRIP-3).  
**Sponsor:** Aker Biomarine  
**Contact:** Travis H. Turner, PhD; turnertr@musc.edu ; 843-577-5011 x5192  
**Description:** This is a RCT examining whether supplementation with phospholipid bound omega-3 improves resiliency to psychophysiological distress in a sample of 400 candidates going through Infantry Basic Officer Leadership Course (IBOLC) and subsequent Ranger training at Ft. Benning. In addition to grades from IBOLC and success/failure in Ranger training, a number of neuropsychiatric measures are included as outcome and mediator/moderator variables.

**Title:** Better Resiliency Among Veterans with Omega-3’s (BRAVO)  
**Sponsor:** Congressionally Directed Medical Research Program.  
**Contact:** Samantha Wise ; wissa@musc.edu ; 843-792-2425  
**Description:** This RCT seeks to determine if dietary supplementation with omega-3 HUFAs reduces the risk for serious suicidal behaviors in an at-risk clinical population. Changes in cognitive processes specific to suicide risk are evaluated, including implicit associations, response inhibition and sustained attention.
Title: Group Motivational Interviewing (GMI) for Homeless Veterans in VA Services
Contact: Kayla Lamb, Kayla.Lamb@va.gov, 843-577-5011 ext: 5310
Description: We are seeking Veterans who are homeless or in the VA Homeless Program to voluntarily enroll in a VA research study comparing two types of treatment for Veterans who have an alcohol misuse problem. Eligible participants will attend one of two groups: a motivational enhancement group therapy, called ‘The Self-Change Program’, designed to enhance motivation to make a healthier change around using substances by exploring personal goals, values, and strengths for making a change, or a Like Skills Educational Group therapy for improving quality of life and enhancing home stability. The study will recruit participants from within three locations: the Charleston VA Medical Center, the Myrtle Beach Community Based Outpatient Clinic (CBOC), and the Savannah, GA CBOC. Compensation will be provided to qualified participants.

Title: A Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel-group, Efficacy and Safety Study of 2 Doses of Dasotraline in Adults with Attention Deficit Hyperactivity Disorder (ADHD)
Contact: Amanda Wagner, wagne@musc.edu, 843-792-0484
Description: This is a randomized, placebo-controlled, double-blind clinical trial (Phase III) evaluating the safety and efficacy of an investigational medication called Dasotraline in adults with Attention Deficit Hyperactivity Disorder. The study requires weekly visits for 12 weeks, and daily medication compliance.

Title: Smart Capsule for Automatic Adherence Monitoring
Contact: Elizabeth Jones, jonesel@musc.edu, 843-792-5819
Description: The purpose of this study is to determine the acceptability, tolerability, and efficacy of capsules with built-in, ingestible sensors that allow researchers to tell whether or not a patient took them as prescribed. This study is recruiting healthy volunteers.

Title: Effects of transcranial Direct Current Stimulation and Brief Cognitive Intervention on Pain Tolerance.
Contact: Brittan Carter, cartebri@musc.edu, (843) 792-3659
Description: The Departments of Psychiatry and Anesthesiology at MUSC are accepting volunteers for a clinical research study to investigate pain tolerance. The purpose of this study is to determine whether a new medical technology, called Transcranial Direct Current Stimulation (tDCS) can temporarily alter pain tolerance level. tDCS is a minimally-invasive technique (i.e., it does not involve any surgical procedures, additional medication or sedation, or needles) that uses a very small amount of electricity to temporarily stimulate specific brain areas in awake people. The electrical current passes through the skin, scalp, hair, and skull and can temporarily increase or decrease activity in areas of the brain that are thought to be involved with pain perception. Interested participants will be screened on the telephone and then have one appointment lasting approximately 1 hour. Participants must be between the ages of 18 and 75. Participation is confidential, and compensation is available.
ONGOING STUDIES

Title: Comparison of Pre-Trial Competency to Stand Trial Defendants’ Characteristics on Outcome of Feigning Measures: A Preliminary Study of Local Norms
Contact: Jennifer Steadham, steadhaj@musc.edu, 876-2140
Description: Deliberate attempts to falsify, fabricate, or grossly exaggerate some aspect of functioning is known as feigning. When feigning is motivated by possibility of external gains (e.g., avoidance of prosecution or lesser punishment), it is known as malingering (Rogers & Shuman, 2005). Malingering has obvious relevance in forensic mental health evaluations, as pre-trial criminal defendants have clear motivations to feign impairment. Feigning strategies can be subdivided into two varieties in criminal forensic contexts: cognitive (i.e., memory or thinking processes) and psychiatric (i.e., symptoms of major mental disorders) impairment. Categorical classifications can be made on the basis of a defendant’s performance on feigning assessment measures, into groups thought to be exaggerating or fabricating impairment (“probable malingers”) or those thought to be responding honestly (“non-malingers”). In the last decade, direct examinations comparing the characteristics of competency defendants suspected of malingering versus non-malingers, as classified by feigning measures, have been sparse and most often included as an incidental question in a larger study. For the current study, a sample of competence to stand trial evaluations conducted by MUSC’s Forensic Psychiatry Program will be reviewed. Competency to stand trial reports dated 2011 through August 2015 will be included for review. Evaluation reports will be coded for examinee (e.g., demographic, psychiatric diagnoses, and mental status descriptions) and evaluator characteristics (i.e., specialty field).

Title: CSP556 “rTMS for depressed veterans”
Contact: Matt Schmidt, matthew.schmidt@va.gov, 843-577-5011 ext 5209
Description: This is study for veterans only who have depression. The treatment given is Transcranial Magnetic stimulation. It is a double blind study with a sham (placebo) possibility. There is a screening phase of about 1 week, a treatment phase of 4-6 weeks, and a follow up phase where subjects come in once per month for 5 months. All procedures and assessments done at Ralph Johnson VA. Subject compensation is available up to $400.00.

Title: A Randomized Trial of E-cigarettes: Natural Uptake, Patterns and Impact of Use
Contact: Caitlyn Hood, hooca@musc.edu, 843-876-2291
Description: Electronic cigarettes (e-cigarettes) are the newest and perhaps the most popular non-cigarette products available to smokers. In this study, we will examine how the use of electronic cigarettes affects smoking behavior. Eligible participants will have a 2/3rds chance of receiving a sample of e-cigarettes. Participants must be current, daily cigarette smokers who are 18 years of age or older and interested in trying the e-cigarette.

Title: Oxytocin in Cocaine Dependence
Contact: Lisa Nunn, jenkinli@musc.edu, 792-0476
Description: This study explores the effect of oxytocin on stress response and brain reactivity in individuals with cocaine dependence. Participation consists of a screening visit, three outpatient study sessions, and two brief follow-up visits.
ONGOING STUDIES

Title: Impulsivity and Drinking/Craving: Effect of a Dopamine Stabilizer Medication
Contact: Mark Ghent, ghent@musc.edu, 792-1222
Description: This non treatment study investigates the effects of a medication in response to alcohol. Individuals (ages 21-40) who complete the study will be paid for their participation. This study does not involve alcohol treatment.

Title: Acceptability and feasibility of the remote monitoring of smoking and relapse in adolescents
Contact: Taylor York, york@musc.edu, 843-792-0493
Description: This is a research study that will test a new remote monitoring technology to assess smoking in the natural environment among adolescents and young adults ages 15-25. After assessment and inclusion in the study, participants will be asked to carry two devices (smartphone and a device to assess how much they are smoking) with them for 11 days and answer questions about their smoking, mood, surroundings, etc. Participants will also be asked to make a brief quit attempt lasting for approximately 48 hours. There is no cost to participate and compensation is available to those who qualify. Remote monitoring technology has the potential for fewer clinic visits and a better understanding of smoking among adolescents and young adults.

Title: A novel approach to reduce the use, misuse and abuse of prescription opioids in pregnancy
Contact: Connie Guille, guille@musc.edu, 843-792-6489
Description: The aim of this study is to gather feedback from pregnant women using prescription opioids who participate in a Cognitive Behavioral Therapy for Chronic Pain program for the reduction of use, misuse and abuse of prescription opioid medication(s).

Title: Adverse early childhood experience and risk for poor obstetric outcomes in African American women
Contact: Connie Guille, guille@musc.edu, 843-792-6489
Description: The aim of this study is to investigate the impact of early childhood adversity on a laboratory stressor and risk for poor obstetric outcomes.

Title: Testing a Promising Treatment for Youth Substance Abuse in a Community Setting
Contact: Dr. Scott W. Henggeler, henggesw@musc.edu, (843) 876-1800
Description: The overriding purpose of the proposed randomized trial is to examine the effectiveness of a promising outpatient treatment of adolescent substance abuse delivered in a community-based treatment setting.

Title: Family-Based Treatment for Parental Substance Abuse and Child Maltreatment
Contact: Dr. Cynthia C. Swenson, swensocc@musc.edu, (843) 876-1800
Description: The purpose of this randomized controlled trial is to examine the effectiveness of the Building Stronger Families Model versus standard services in Connecticut for physically abuse and/or neglected children whose parents are experiencing severe substance abuse. The study is being implemented through a community based mental health provider. Key outcomes under examination include child behavior, parent behavior, family relations, parent to child violence, reabuse, placement, and parental substance abuse.
Title: rTMS for Adolescent Depression -- upcoming in the next couple weeks  
Contact: Annabel Franz, franza@musc.edu, 843-876-5141  
Description: We are investigating the safety and efficacy of repetitive TMS as a treatment for adolescent depression for those aged 12-21 years old. We are seeking adolescents of this age range who have not received sufficient benefit from at least one antidepressant medication trial. TMS is currently FDA approved for treating adult depression.

Title: rTMS for Bipolar Depression - current  
Contact: Annabel Franz, franza@musc.edu, 843-876-5141  
Description: We are investigating repetitive TMS as a treatment for bipolar depression in conjunction with mood stabilizers in adults aged 22-68 years old. We are seeking treatment refractory patients with bipolar disorder. TMS is currently FDA approved for treating adult depression.

Title: rTMS for Reducing Marijuana Craving and Risky Behaviors in Non-Treatment Seeking Heavy Marijuana Smokers - current  
Contact: Annabel Franz, franza@musc.edu, 843-876-5141  
Description: A pilot trial investigating how TMS to the left dorso-lateral pre-frontal cortex can reduce marijuana craving and impulsive decisions in adults 18-60.

Title: Enhancing Disrupted Reconsolidation: Impact on Cocaine Craving, Reactivity & Use  
Contact: Amanda Smith, smitham@musc.edu, 792-6984  
Description: The purpose of this double-blind, placebo-controlled study is to examine whether beta-adrenergic antagonist propranolol can attenuate cocaine-associated memories and thereby reduce cocaine craving, cue reactivity, and use in cocaine dependent participants. Participants will receive either placebo, 40mg, or 80mg of propranolol after each of two laboratory sessions of cocaine cue exposure. Participants will be evaluated on cocaine craving, physiological reactivity to cocaine cues, and cocaine use in follow-up sessions for 6 weeks.

Title: Traumatic Exposure and Competency to Stand Trial: Describing Juvenile Offender Characteristics.  
Contact: Sheresa Christopher, chrisshe@musc.edu, 792-1461  
Description: Exposure to traumatic events is associated with trauma sequelae which has been studied and observed in samples of justice-involved youth. Within this population, a small subset of youth is referred for evaluation of their competency to stand trial due to concerns they may be lacking a factual and rational understanding of the proceedings against them and the ability to assist their attorney in their defense. Despite the high prevalence of trauma exposure and the similarity of deficits observed, little is known about trauma exposure in youth thought to exhibit deficits in those abilities typically associated with competency to stand trial. The current study aims to describe the differences in characteristics between juveniles who are opined competent to stand trial and those who are not. A particular emphasis is placed on the presence and type of past trauma exposure in relation to the nature of the criminal offenses given the high prevalence of trauma in this population.
Title: Psychological First Aid for Victims of Crime  
Contact: Dr. Michael McCart, mccartm@musc.edu, (843) 876-1800  
Description: This study aims to implement and refine research protocols required for a full-scale randomized clinical trial of Psychological First Aid (PFA) for adult victims of crime. PFA is a promising acute intervention designed to reduce the severity and duration of trauma-related distress. Law Enforcement Victim Advocates are being trained to implement PFA with adult crime victims. A pilot trial is comparing PFA to usual services on key mental health outcomes from baseline through 4 months post-baseline.

Title: Synthesizing HIV Behavioral Intervention Effectiveness in Developing Countries  
Contact: Dr. Michael D. Sweat, sweatm@musc.edu, (843) 876-1800  
Description: This is a project in which we are conducting systematic reviews and meta-analysis on evidence of effectiveness of a variety of HIV behavioral interventions in developing countries.

Title: Phase II RCT of Comprehensive Triage HIV Prevention: Tanzania  
Contact: Dr. Michael D. Sweat, sweatm@musc.edu, (843) 876-1800  
Description: The purpose of this study is to conduct a rigorous 3-year Phase II trial of a promising HIV prevention strategy designed to significantly reduce population-level HIV incidence in rural developing country settings with severe generalized HIV epidemics.

Title: Community-Based Combination HIV Prevention in Tanzania Women at Heightened Risk  
Contact: Dr. Michael D. Sweat, sweatm@musc.edu, (843) 876-1800  
Description: This is a two-arm Phase II community randomized controlled trial of a community-based combination HIV prevention intervention among FSWs in Iringa, Tanzania. The combination package examined includes integrated biomedical, behavioral and structural components: The study will establish base rates of key outcomes including HIV incidence and viral load suppression, examine the socio-structural and behavioral pathways of the intervention, assess feasibility, acceptability and safety, and document preliminary effectiveness. (1) mobile HIV testing and risk reduction counseling; (2) service navigation to facilitate access to treatment and retention in care; (3) sensitivity training for HIV clinical care providers; (4) SMS text messages to promote adherence to care and ART; (5) venue-based peer education and condom distribution; and (6) a community drop-in center to promote cohesion and collective action to reduce stigma and discrimination.

Title: Dyadic-Based Diagnosis, Care & Prevention for Discordant Couples in Tanzania  
Contact: Dr. Michael D. Sweat, sweatm@musc.edu, (843) 876-1800  
Description: The primary goal for the proposed study is to examine the feasibility, safety, and impact on improved care and prevention of novel strategies to identify and engage HIV sero-discordant couples in an integrated prevention and treatment intervention.
Title: A Phase 2, Efficacy, Safety, and Tolerability Study of ALKS 3831 in Schizophrenia with Alcohol Use Disorder.

Contact: Melissa Michel, michelm@musc.edu, 843-792-1901

Description: This study is designed to evaluate the efficacy, safety, and tolerability of ALKS 3831 in schizophrenia with AUD. ALKS 3831 is a combination of olanzapine, an approved antipsychotic treatment for schizophrenia, and samidorphan, a new medication. Potential subjects for this trial are adults with a diagnosis of schizophrenia and alcohol use disorder (AUD) with a recent change in symptoms. The study will test whether olanzapine with samidorphan will aide in lowering alcohol use for subjects at the same time that the combination of the two drugs lessens side effects of olanzapine such as weight gain.

Title: An Open-label, Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression

Contact: Melissa Michel, michelm@musc.edu, 843-792-1901

Description: The main purpose of this study is to assess the long-term safety, tolerability, and effectiveness of esketamine nasal spray plus a newly initiated oral (taken by mouth) antidepressant in patients with treatment-resistant depression. All patients in this study will be treated with esketamine nasal spray plus a new oral anti-depressant. The new oral anti-depressant will be one of the following approved and marketed oral antidepressants: duloxetine (Cymbalta), escitalopram (Lexapro), sertraline (Zoloft), or venlafaxine extended release (Effexor XR).

****Anticipated to start January 2016

Title: Internet Crimes Against Children: Development of a Typology of Offenders for Use in Prevention, Investigations and Treatment

Contact: Dr. Gregg Dwyer, 843-792-1461

Description: This study is based on the collection and analysis of data from Internet Crimes against Children (ICAC) investigated by ICAC Task Forces in 20+ states. The inferential analysis of perpetrator, victim and offense data and content analysis of Internet chats to solicit children serves to inform the mental health, social services, education and legal fields for use in forensic evaluations, treatment planning, criminal investigations, court proceedings and developing public safety strategies for protecting our communities’ youth. Funded by Office of Juvenile Justice and Delinquency Prevention grant # 2010-MC-CX-4003; joint with the University of So. Carolina.

Title: Protecting Children Online: Using Research-Based Algorithms to Prioritize Law Enforcement Internet Investigations

Contact: Dr. Dwyer. 843-792-1461

Description: Using data from ICAC Task Forces across the U.S. to develop empirically-based algorithms to assist law enforcement in prioritizing cases of: child pornography production over possession/distribution; online luring to meet a minor to commit sexual offenses, over luring restricted to online behavior such as sexual chat or exchanging pornographic images; hands-on sexual offense offenders against children over cases of offenders with no known history. Funded by Office of Juvenile Justice and Delinquency Prevention grant # 2011-MC-CX-0002; joint with University of South Carolina, Johns Hopkins University & University of Ottawa.
ONGOING STUDIES

Title: Rivastigmine Patch in Veterans with Cognitive Impairment Following Traumatic Brain Injury
Contact: Katy Donovan donova@musc.edu (843) 724-2945
Description: In light of the significance of memory deficits in persons with Traumatic Brain Injury (TBI), and the strong relationship between posttraumatic memory impairments and posttraumatic cholinergic dysfunction, this study examines the efficacy and safety of cholinesterase inhibitor rivastigmine (transdermal patch), an intermediate-acting cholinesterase inhibitor, in Veterans (ages 19 – 65 years old) suffering from posttraumatic memory impairment following TBI in a multicenter, randomized placebo controlled 26-week trial.

Title: Apathy in Dementia Methylphenidate Trial 2 (ADMET 2)
Contact: Olga Brawman-Mintzer, MD mintzero@musc.edu; (843) 724-2945
Description: Apathy in Dementia Methylphenidate Trial 2 (ADMET 2) is a Phase III, placebo-controlled, masked, 6 month, 10-center randomized clinical trial sponsored by National Institute of Aging involving 200 participants with Alzheimer's disease (AD). ADMET 2 is designed to examine the efficacy and safety of methylphenidate as treatment for clinically significant apathy in AD participants. ADMET 2 will enroll participants from real world settings such as outpatient, nursing home, and assisted living facilities and will examine the effects of methylphenidate on apathy and cognition. ADMET 2 will also conduct careful safety monitoring.
ONGOING STUDIES

Title: Eagle Eye: Validation of computer-based saccade measures as a sensitive, reliable, and freely available biomarker for tracking subtle neurocognitive changes in Parkinson's disease.
**Sponsor:** Michael J. Fox Foundation  
**Contact:** Jenna Renfroe, PhD.; renfroe@musc.edu ; 843-792-6096  
**Description:** This study aims to validate a computer-based task to enable clinicians and researchers to measure saccades without the cost and complexity of traditional eye-tracking equipment.

Title: Development and standardization of an iPhone-based application for quantitative measurement of the pupillary light reflex in healthy adults and patients with Parkinson’s disease. (iDilate)  
**Sponsor:** Chairs Departmental Research Foundation  
**Contact:** Jenna Renfroe, PhD; renfroe@musc.edu ; 843-792-6096  
**Description:** This aim of this project is to develop and standardize an application that would allow clinicians, researchers, and community-based safety personnel (e.g., police and EMS) to obtain quantitative measurements of the pupillary light reflex, a highly sensitive measure of neurological functioning.

Title: Atomoxetine Treatment for Cognitive Impairment in Parkinson’s Disease (ATM-Cog).  
**Sponsor:** Michael J. Fox Foundation  
**Contact:** Vanessa Hinson, MD, PhD.; hinsonvk@musc.edu ; 843-792-6096  
**Description:** This is a RCT assessing the safety and efficacy of ATM for cognitive impairment in Parkinson’s disease.

Title: Ranger Resilience and Improved Performance on phospholipid bound Omega-3’s (RRIP-3).  
**Sponsor:** Aker Biomarine  
**Contact:** Travis H. Turner, PhD; turnertr@musc.edu ; 843-577-5011 x5192  
**Description:** This is a RCT examining whether supplementation with phospholipid bound omega-3 improves resiliency to psychophysiological distress in a sample of 400 candidates going through Infantry Basic Officer Leadership Course (IBOLC) and subsequent Ranger training at Ft. Benning. In addition to grades from IBOLC and success/failure in Ranger training, a number of neuropsychiatric measures are included as outcome and mediator/moderator variables.

Title: Better Resiliency Among Veterans with Omega-3’s (BRAVO)  
**Sponsor:** Congressionally Directed Medical Research Program.  
**Contact:** Samantha Wise ; wissa@musc.edu ; 843-792-2425  
**Description:** This RCT seeks to determine if dietary supplementation with omega-3 HUFAs reduces the risk for serious suicidal behaviors in an at-risk clinical population. Changes in cognitive processes specific to suicide risk are evaluated, including implicit associations, response inhibition and sustained attention.
ONGOING STUDIES

Title: Effect of Pregnenolone on Cue-Reactivity in Marijuana-Dependent Individual.
Contact: Lisa Nunn, jenkinli@musc.edu, 792-0476
Description: This study explores the impact of an oral medication, pregnenolone, on drug craving following exposure to marijuana cues. Participation consists of a screening visit and one study session.

Title: Neural Substrates of Emotion: Impact of Cocaine Dependence
Contact: Lisa Nunn, jenkinli@musc.edu, 792-0476
Description: This study explores the effect of oxytocin on brain activity associated with stress in cocaine dependent individuals. Participation consists of a screening visit and one study session.

Title: A Randomized Controlled Trial of Varenicline for Adolescent Smoking Cessation (formal title protocol); Project Quit (nickname)
Contact: Referrals – Team Intake Coordinator; Study Management - Lori Ann Ueberroth, Study Coordinator
Contact email: Referrals – smokingstudy@musc.edu; Study Management – ueberro@musc.edu
Contact phone number: Referrals – 792-4097; Study Management – 792-8220
Description: This is a research study to determine if a medication (varenicline) helps young cigarette smokers quit. Smokers aged 14-21 who participate in the study receive medication or placebo and help with quitting during 12 weekly sessions. Smokers under 18 must have parental consent. There is no cost to participate and compensation is available to those that qualify.

Title: The gender-sex hormone interface with craving & stress-related changes in smoking (formal title protocol); SCOR 3 Nicotine (nickname)
Contact: Referrals – Team Intake Coordinator; Study Management - Lori Ann Ueberroth, Study Coordinator
Contact email: Referrals – smokingstudy@musc.edu; Study Management – ueberro@musc.edu
Contact phone number: Referrals – 792-4097; Study Management – 792-8220
Description: This is a non-treatment study for cigarette smokers ages 18-45, examining gender and reproductive hormone influences on smoking behavior. There is NO requirement that participants be interested in quitting smoking. The study involves 4 clinic visits and compensation is provided for those who qualify.

Title: Gabapentin for Relapse Prevention: Alcohol Withdrawal-Brain GABA/Glutamate Effects
Contact: Konstantin Voronin, voronin@musc.edu, 792-4887
Description: This treatment study is an 16-weeks outpatient clinical trial where subjects will get medication, which might help them to reduce or stop their drinking, or a placebo. This study will recruit and randomize subjects who have expressed an interest in receiving treatment for alcohol dependence. Upon enrollment into this study there will be 11 outpatient visits. Each visit will last about 1-1.5 hours.
Title: Impulsivity and Drinking/Craving: Effect of a Dopamine Stabilizer Medication  
Contact: Mark Ghent, ghent@musc.edu, 792-1222  
Description: This non treatment study investigates the effects of a medication in response to alcohol. Individuals (ages 21-40) who complete the study will be paid for their participation. This study does not involve alcohol treatment.

Title: Acceptability and feasibility of the remote monitoring of smoking and relapse in adolescents  
Contact: Taylor York, york@musc.edu, 843-792-0493  
Description: This is a research study that will test a new remote monitoring technology to assess smoking in the natural environment among adolescents and young adults ages 15-25. After assessment and inclusion in the study, participants will be asked to carry two devices (smartphone and a device to assess how much they are smoking) with them for 11 days and answer questions about their smoking, mood, surroundings, etc. Participants will also be asked to make a brief quit attempt lasting for approximately 48 hours. There is no cost to participate and compensation is available to those who qualify. Remote monitoring technology has the potential for fewer clinic visits and a better understanding of smoking among adolescents and young adults.

Title: A novel approach to reduce the use, misuse and abuse of prescription opioids in pregnancy  
Contact: Connie Guille, guille@musc.edu, 843-792-6489  
Description: The aim of this study is to gather feedback from pregnant women using prescription opioids who participate in a Cognitive Behavioral Therapy for Chronic Pain program for the reduction of use, misuse and abuse of prescription opioid medication(s).

Title: Adverse early childhood experience and risk for poor obstetric outcomes in African American women  
Contact: Connie Guille, guille@musc.edu, 843-792-6489  
Description: The aim of this study is to investigate the impact of early childhood adversity on a laboratory stressor and risk for poor obstetric outcomes.

Title: Testing a Promising Treatment for Youth Substance Abuse in a Community Setting  
Contact: Dr. Scott W. Henggeler, henggesw@musc.edu, (843) 876-1800  
Description: The overriding purpose of the proposed randomized trial is to examine the effectiveness of a promising outpatient treatment of adolescent substance abuse delivered in a community-based treatment setting.

Title: Family-Based Treatment for Parental Substance Abuse and Child Maltreatment  
Contact: Dr. Cynthia C. Swenson, swensocc@musc.edu, (843) 876-1800  
Description: The purpose of this randomized controlled trial is to examine the effectiveness of the Building Stronger Families Model versus standard services in Connecticut for physically abuse and/or neglected children whose parents are experiencing severe substance abuse. The study is being implemented through a community based mental health provider. Key outcomes under examination include child behavior, parent behavior, family relations, parent to child violence, reabuse, placement, and parental substance abuse.
ONGOING STUDIES

Title: Positive Psychotherapy to Improve Autonomic Function and Mood in ICD Patients
PAM-ICD Trial (NCT02088619)
Contact : Dr. Lily Christon (Project Coordinator); Dr. Eva Serber (PI)
Contact email: pam-icd@musc.edu
Contact phone number: 843-792-0625
Description: This study is a randomized clinical trial of a positive-emotion focused cognitive-behavioral therapy intervention (Quality of Life Therapy) vs. a heart healthy education intervention among patients with implantable cardioverter defibrillators (ICD), with the primary aim of feasibility and acceptability of QOLT in ICD patients. Secondary aims include obtaining effect size estimates of QOLT on frequencies of arrhythmia episodes and ICD-delivered therapies, parasympathetic activity and regulation, and QOL and psychosocial constructs. Recruitment: patients of MUSC Cardiology

Title: TMS for nicotine addiction
Contact: Scott Henderson or Xingbao Li
Contact email:  henderjs@musc.edu or lixi@musc.edu
Contact phone: 843-792-5560 or 843-792-5729
Description: This is a double blind randomized controlled smoking cessation research study sponsored by the National Institute of Drug Abuse. This study is designed to ascertain whether repetitive transcranial magnetic stimulation (rTMS) can affect things that may prompt you to want to smoke and the consumption of cigarettes over a 3-month period. After assessment and inclusion into the study, participants will be randomized to receive a 10-time active rTMS or placebo-like rTMS. Participants must be (1) current cigarette smokers; (2) between 18-60 years old; (3) able to commit approximately 13 hours of time to the study; and (4) have no metal in their body. Compensation will be provided.

Title: Integrative Risk Reduction and Treatment for PTSD and Teen Substance Use Problems
Contact: Liz McGuan, mcguan@musc.edu, 843-792-8361
Description: This program involves a randomized controlled trial (RCT) with subjects ages 13-18 years who have experienced interpersonal violence (physical or sexual abuse/assault, exposure to domestic violence, witness community violence). Subjects are randomized to either receive Risk Reduction through Family Therapy (RRFT) or Treatment As Usual (TAU). Youth will be recruited from local child advocacy centers and the interventions are psychosocial in nature. Follow-up assessments will be conducted at multiple time points through 18-month post entry.

Title: Investigation of safety and efficacy of once-daily semaglutide in obese subjects without diabetes mellitus
Contact: Suzanne Kuker, kuker@musc.edu, 792-5427
Description: This study seeks to determine whether semaglutide, will help non-diabetic people who are obese to lose weight over one year. Participants will be randomly assigned to receive 1 of 5 doses of semaglutide, liraglutide or an inactive placebo and will be enrolled in the study for 59 weeks. The primary measure will be weight change and other measures will include health factors related to obesity such as blood sugar control, blood pressure, and cholesterol. The safety of the drug for weight loss will also be studied.
SUPPORTERS

Water's Edge Dentistry
Excellence in Cosmetic, Restorative & Family Dentistry

"Dr D" is In-Network for the MUSC Health Plan
She proudly uses her award-winning talents to service the Lowcountry community.

Committed to giving you the smile you deserve:
- Family/General Dentistry
- Cosmetic Dentistry
- TMJ - Clenching/Grinding
- Sleep Apnea & Snoring
- Invisalign Braces
- Anxiety-Free Dentistry
- Botox/Dermal Fillers
- Teeth Whitening

Free In Office Whitening With New Patient Exam
Expires 3/1/16

WatersEdgeSC.com / 843.884.6166
1203 Two Island Court, #101, Mount Pleasant, SC 29466
(just off the Isle of Palms Connector)